Lineage shifts in acute lymphoblastic leukemia (ALL) are uncommon and if they occur usually involve a switch from lymphoid to myeloid lineage. [1] [2] [3] [4] Here we report the observation of a B-to T-cell switch in a BCR-ABL1 positive B-ALL that was engrafted in immune deficient NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice. We studied the engraftment of 4 BCR-ABL1 positive B-ALL cases ( Table 1) , and observed the unexpected appearance of a BCR-ABL1 positive T-ALL for 1 of the 4 cases (XC49). These data indicate that a switch from B-ALL to T-ALL is possible, and that this could be a novel mechanism to develop resistance against anti-CD19 directed therapy in some B-ALL cases.
Indeed, with the introduction of CD19-directed immunotherapy for the treatment of B-cell malignancies, clinicians were suddenly confronted with previously unobserved tumor escape mechanisms. More and more patients present themselves at relapse with a downregulation or alteration of the CD19 surface antigen on their malignant cells or with an acquired extramedullary invasion. [5] [6] [7] [8] [9] [10] [11] [12] In a recent study, Nagel et al described an alternative escape route for malignant B-ALL cells after receiving anti-CD19 directed therapy. They presented 2 cases of BCR-ABL1 positive B-ALL who experienced a CD19-negative myeloid lineage relapse after blinatumomab treatment. Using fluorescence in situ hybridization, the authors confirmed the presence of the BCR-ABL1 fusion in the hematopoietic stem cell (HSC) compartment of both patients. Investigation of an additional 25 BCR-ABL1 positive B-ALL cases revealed that up to 40% of the patients had HSC involvement. Interestingly, HSCs were more often involved in patients carrying the major BCR-ABL1 transcript encoding P210 BCR-ABL1 than patients carrying minor BCR-ABL1 transcripts encoding P190 BCR-ABL1 . 13 Here, we describe a B to T lineage shift in a patient-derived xenograft (PDX) model from a childhood BCR-ABL1 positive, CD19-positive B-ALL (case XC49, Table 1 ). This 3-year-old female patient was admitted to the hospital with fever and musculoskeletal pain. Clinical and laboratory investigations revealed hepatosplenomegaly with signs of anemia and moderate thrombocytopenia in the peripheral blood. White blood cell counts were elevated, up to 60,000 cells/mm 3 , with 58% blast cells and a bone marrow smear revealed a blast cell count of 80%. Karyotyping and MLPA investigation identified a t(9;22)(q34; q11) resulting in the BCR-ABL1 fusion transcript e1a2 (P190). Karyotyping also detected hyperdiploidy of chromosomes X, 4, 9, 10, 14, 21, and 22. IgH and IgK were monoclonal, as was the T-cell receptor gamma, which was consistent with a monoclonal B-cell proliferation with illegitimate T-cell receptor rearrangement. The patient was diagnosed with high risk B-ALL, exceptionally carrying both a P190 BCR-ABL1 fusion transcript and a hyperdiploid phenotype. Treatment was given according to the EsPhALL protocol and imatinib was associated during induction chemotherapy. Minimal residual disease investigations were negative after induction therapy, but unfortunately the child deceased 10 months after initial diagnosis, due to treatment side effects.
Bone marrow and peripheral blood samples were collected both at diagnosis and after induction when the patient was in complete remission, according to protocol S57176 approved by the Ethical Committee of the University Hospital of Leuven. Written informed consent was obtained. Mononuclear cells were isolated from the samples using Ficoll-Paque and used for RNA and DNA extraction. Whole genome sequencing (WGS) of the patient sample at diagnosis compared to remission confirmed the presence of a P190 BCR-ABL1 fusion transcript and the hyperdiploidy of chromosomes X, 4, 9, 10, 14, 21 and part of chromosome 22 (Fig. 1A) . Flow cytometry of the cells revealed a CD19-positive, CD34-positive phenotype of the leukemia cells ( Fig. 1B) .
Diagnostic mononuclear cells were injected into the tail vein of seven 6-to-12-week old NSG mice for further leukemic expansion and analysis. Blood samples were taken once every 2 weeks and measured on a Vet ABC Hematology Analyzer (SCIL). Leukemic engraftment was determined with flow cytometry (FACS Canto II, BD, San Jose, CA) using antihuman CD19 (FITC, eBioscience, Waltham, MA) as a marker for the leukemic cells. Of the 7 mice that were injected, 3 were sacrificed after 41 to 77 days due to ethical end points (without signs of CD19-positive cells), while the remaining 4 animals showed successful engraftment of the CD19-positive B-ALL and were sacrificed 10 to 20 days later (Fig. 1C) . Staining of the splenic and bone marrow cells revealed that the first 3 animals developed a weak CD34-positive, CD19-negative leukemia and that these leukemic cells were positive for CD2, CD5, and cytoplasmic CD3. The expression of CD4, CD8, and CD7 varied between the xenografts. Engraftment was lower (23-32% based on intracellular human CD3) than for the other 4 xenografted animals, which showed invasion of their spleens with >80% CD19-positive, CD34-positive leukemia cells, similar to the B-ALL of the patient (Fig. 1D-G) . Leukemic cells from both the T-and B-ALL PDX model were transplantable into secondary recipients (data not shown).
We next investigated the presence of the BCR-ABL1 fusion in cDNA and DNA derived from bone marrow and spleen cells of the xenografted animals. The BCR-ABL1 fusion was detected in all animals irrespective of B-ALL or T-ALL immunophenotype. The exact same BCR and ABL1 breakpoints (determined by whole exome sequencing, Fig. 1A) were detected at genomic level in B-and T-ALL, confirming that the T-ALL originated from the same leukemia stem cells (Fig. 1H) .
In 1999, Winter et al 14 reported an unusual pre-B ALL case with b3a2 (P210) and e1a2 (P190) BCR-ABL1 fusion transcripts that relapsed as chronic myeloid leukemia carrying only the less differentiated b3a2 (P210) clone. This case report already alluded on the existence of precursor cells with both myeloid and lymphoid potential involved in BCR-ABL1 leukemia development. More recently, Nagel et al reported that up to 40% of the BCR-ABL1 positive B-ALL patients had HSC involvement, and linked that to the possibility for B to myeloid leukemia shifts during anti-CD19 directed therapy. Here, we describe yet another possible mechanism for escape to anti-CD19 therapy by switching from B-to T-ALL. Our data provide additional evidence for the existence of CD19-negative, BCR-ABL1 positive leukemia stem cells in B-ALL.
Our patient carried a minor BCR-ABL1 transcript P190 BCR-ABL1 , which is, according to Castor et al, 15 precluded to the B-cell progenitor stage. Although Nagel et al also primarily found HSC-involvement in patients carrying major BCR-ABL1 transcript encoding P210 BCR-ABL1 , they did detect HSC-involvement in 3 out of 12 patients with minor P190 BCR-ABL1 transcripts. 13 While BCR-ABL1 translocations can occur in T-ALL, they are very rare and the NUP214-ABL1 fusion is more common in T-ALL. [16] [17] [18] Our data however indicate that the increasing use of CD19-directed therapies may guide leukemic cells to more inventive escape mechanisms, not only by relapsing as CD19-negative, BCR-ABL1 positive myeloid leukemia, but possibly also as CD19-negative, BCR-ABL1 positive T-ALL. (2018) 2:3 www.hemaspherejournal.com
